Enliven Therapeutics (ELVN) Interest Expenses (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Interest Expenses data on file, last reported at $104000.0 in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 25.3% year-over-year to $104000.0; the trailing twelve-month figure through Mar 2026 stood at $348000.0 (up 16.78% YoY), and the FY2025 full-year result was $27.8 million, down 59.82% from the prior year.
• Interest Expenses slipped to $104000.0 in Q1 2026, from $117000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $35.7 million in Q4 2023 to a low of $20000.0 in Q1 2023.
• A 5-year average of $3.4 million and a median of $117000.0 in 2025 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 42402.17% in 2022 and tumbled 99.88% in 2024, its largest moves.
• Tracing ELVN's Interest Expenses over 5 years: stood at $19.6 million in 2022, then surged by 82.56% to $35.7 million in 2023, then plunged by 99.88% to $44000.0 in 2024, then soared by 165.91% to $117000.0 in 2025, then dropped by 11.11% to $104000.0 in 2026.
• Business Quant data shows ELVN's Interest Expenses at $104000.0 in Q1 2026, $117000.0 in Q4 2025, and $514000.0 in Q3 2025.